Company Overview and News

 
KMG Chemicals, Black Hills, CounterPath, eGain and SeaChange International highlighted as Zacks Bull and Bear of the Day

2017-12-29 zacks
Chicago, IL – Dec 29, 2017 – Zacks Equity Research highlights KMG Chemicals (KMG - Free Report) as the Bull of the Day and Black Hills Corporation (BKH - Free Report) as the Bear of the Day. In addition, Zacks Equity Research provides analysis ontheCounterPath, Corp. (CPAH - Free Report) , eGain Corporation (EGAN - Free Report) and SeaChange International, Inc. (SEAC - Free Report) .

 
Zacks.com highlights: Sprouts Farmers Market, Thor Industries, Hibbett Sports, Patrick Industries and PetMed Express

2017-12-29 zacks
Chicago, IL – Dec 29, 2017 - Stocks in this week’s article include: Sprouts Farmers Market Inc. (SFM - Free Report) , Thor Industries Inc. (THO - Free Report) , Hibbett Sports Inc. (HIBB - Free Report) , Patrick Industries Inc. (PATK - Free Report) and PetMed Express Inc. (PETS - Free Report) .

 
Zacks Industry Outlook Highlights: American Equity Investment Life Holding, Reinsurance Group of America and Lincoln National

2017-12-29 zacks
Chicago, IL – Dec 29, 2017 – Today, Zacks Equity Research discusses the Industry: Insurance, Part 2, including American Equity Investment Life Holding Company (AEL - Free Report) , Reinsurance Group of America (RGA - Free Report) and Lincoln National Corp. (LNC - Free Report) .

1
The Zacks Analyst Blog Highlights: Innovative Industrial Properties, Constellation Brands, Boston Beer, British American Tobacco and Las Vegas Sands

2017-12-29 zacks
Chicago, IL – Dec 29, 2017 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Innovative Industrial Properties Inc (IIPR - Free Report) , Constellation Brands, Inc. (STZ - Free Report) , Boston Beer Company Inc (SAM - Free Report) , British American Tobacco PLC (BTI - Free Report) and Las Vegas Sands Corp.

 
The Zacks Analyst Blog Highlights: Tailored Brands, American Axle & Manufacturing Holdings, Summit Midstream Partners, Community Bank System and Park National

2017-12-29 zacks
Chicago, IL – Dec 29, 2017 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Tailored Brands, Inc. (TLRD - Free Report) , American Axle & Manufacturing Holdings, Inc. (AXL - Free Report) , Summit Midstream Partners, LP (SMLP - Free Report) , Community Bank System, Inc.

 
The Zacks Analyst Blog Highlights: ACADIA Pharmaceuticals, Sangamo Therapeutics, AnaptysBio and Sino Biopharmaceutical

2017-12-28 zacks
Chicago, IL – Dec 28, 2017 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include ACADIA Pharmaceuticals Inc. (ACAD - Free Report) , Sangamo Therapeutics, Inc. (SGMO - Free Report) , AnaptysBio (ANAB - Free Report) and Sino Biopharmaceutical Limited (SBMFF - Free Report) .

1
4 Biotech Stocks Ready to Crush the Market in 2018

2017-12-27 zacks
The year 2017 has been quite a impressive one for the biotech sector as evident from the 19.4% gain registered so far by the NASDAQ Biotechnology Index (^. This is surely welcome news for investors since the industry suffered a decline of 19.2% last year.

 
Cancer, hepatitis treatments set for boost as China overhauls drugs list

2017-01-26 reuters
SHANGHAI China is set to add more than 300 new and traditional drugs to its list of medicines the state will help patients pay for, the first change in more than seven years that will boost treatments for cancer, kidney disease, hepatitis and haemophilia.

 
Cancer, hepatitis treatments set for boost as China overhauls drugs list

2017-01-26 channelnewsasia
SHANGHAI: China is set to add more than 300 new and traditional drugs to its list of medicines the state will help patients pay for, the first change in more than seven years that will boost treatments for cancer, kidney disease, hepatitis and haemophilia.

 
Annual Financial Report

2016-12-09 londonstockexchange
The Directors of JPMorgan Chinese Investment Trust plc announce the Company's results for the year ended 30th September 2016.

 
Sino Biopharm: Bad Corporate Governance On Display

2016-09-18 seekingalpha
On June 1st, the Chairman of Sino Biopharmaceutical (OTCPK:SBMFF) entered into an agreement with the company which gives him control of Beijing Tide, a subsidiary of the company, which is set to list on the A-share market. Had control of the company stayed at the Company, there would certainly be much more value to a potential acquirer.

 
HK-listed biotechnology technology shares set to reap windfall from hunt for ‘Zika’ cure

2016-09-11 scmp
Companies engaged in vaccine development, research, MAB, and liquid biopsy set to gain as they develop products to tackle deadly disease

 
What Are the Chief Causes behind GSAGX’s Terrible 2016?

2016-07-01 marketrealist
The Goldman Sachs Asia Equity Fund Class A (GSAGX) has had a terrible 2016 so far. It stands dead last among its nine peers in this review YTD (year-to-date) in 2016. Except for the one-year period, in which it ranks sixth, the fund has placed among the bottom two funds across periods.

 
Half-year Results 2016

2016-06-09 londonstockexchange
Over the six months ended 31st March 2016, the Company's return on net assets was 9.0% and the return to Ordinary shareholders 8.3%, reflecting a widening of the Company's discount over the period. The Company underperformed its benchmark, the MSCI Asia ex Japan Index, which returned 11.4%.

 
More funds expected to quit Chinese stocks

2016-01-16 scmp
Energy and utilities sectors to bear brunt of sell-off as investors pull out on concerns over US interest rates and weak commodities prices

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

8h - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

8h - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

18h - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...